SI-BONE, Inc. (SIBN)

NASDAQ: SIBN · IEX Real-Time Price · USD
18.13
+0.73 (4.20%)
Aug 18, 2022 4:00 PM EDT - Market closed
4.20%
Market Cap 621.95M
Revenue (ttm) 95.54M
Net Income (ttm) -66.27M
Shares Out 34.30M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 423,996
Open 17.21
Previous Close 17.40
Day's Range 16.88 - 18.30
52-Week Range 11.89 - 25.41
Beta 1.35
Analysts Buy
Price Target 25.06 (+38.2%)
Earnings Date Aug 8, 2022

About SIBN

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFu... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Oct 17, 2018
CEO Jeffrey Dunn
Employees 352
Stock Exchange NASDAQ
Ticker Symbol SIBN
Full Company Profile

Financial Performance

In 2021, SI-BONE's revenue was $90.15 million, an increase of 22.84% compared to the previous year's $73.39 million. Losses were -$56.57 million, 29.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for SIBN stock is "Buy." The 12-month stock price forecast is 25.06, which is an increase of 38.22% from the latest price.

Price Target
$25.06
(38.22% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 50%: Here's is How to Trade

The mean of analysts' price targets for Si-Bone (SIBN) points to a 49.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

Si-Bone (SIBN) delivered earnings and revenue surprises of -10.20% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022

SANTA CLARA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported fin...

Analysts Estimate Si-Bone (SIBN) to Report a Decline in Earnings: What to Look Out for

Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SI-BONE To Report Second Quarter 2022 Financial Results on August 8, 2022

SANTA CLARA, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced i...

SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System

Use Includes Pelvic Fragility Fractures Use Includes Pelvic Fragility Fractures

SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite, a Breakthrough Pelvic Fixation and Fusion Tech...

SANTA CLARA, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anato...

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

Si-Bone (SIBN) delivered earnings and revenue surprises of -20.93% and 0.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

SI-BONE, Inc. Reports First Quarter 2022 Financial Results

SANTA CLARA, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported fina...

Earnings Preview: Si-Bone (SIBN) Q1 Earnings Expected to Decline

Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SI-BONE, Inc. Announces New Technology Add-On Payment for Breakthrough Adult Spinal Deformity Treatment

SANTA CLARA, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN) a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anat...

SI-BONE To Present at BofA Securities 2022 Healthcare Conference

SANTA CLARA, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced ...

SI-BONE, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Issues 2022 Revenue Guidance

SANTA CLARA, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported fin...

SI-BONE To Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

SANTA CLARA, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced i...

SI-BONE to participate in 24th Annual Needham Virtual Growth Conference

SANTA CLARA, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anat...

Mainstay Medical Announces Appointment of Jeffrey Dunn and Eric Major to its Board of Directors

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company's board of directors, Jeffrey Dunn and Eric Major. These appointments...

SI-BONE, Inc. Announces Updated Exclusive Blue Cross Blue Shield Association Evidence Street Opinion, and New Coverag...

Policies clarify that only iFuse Transiliac Triangular Implants are covered, and that no other products should be used based on published clinical evidence Policies clarify that only iFuse Transiliac Tr...

Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates

Si-Bone (SIBN) delivered earnings and revenue surprises of -17.07% and -1.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SI-BONE, Inc. Reports Third Quarter 2021 Financial Results and Updates 2021 Financial Guidance

SANTA CLARA, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported fin...

Earnings Preview: Si-Bone (SIBN) Q3 Earnings Expected to Decline

Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SI-BONE To Report Third Quarter 2021 Financial Results on November 8, 2021

SANTA CLARA, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced i...

SI-BONE, Inc. Announces UnitedHealthcare Adopts Exclusive iFuse Only Coverage for Minimally Invasive SI Joint Fusion

The transition to an exclusive triangular implant policy by UnitedHealthcare, the nation's largest health insurer, is supported by over 100+ peer-reviewed publications, and comes as SI-BONE surpasses 60...

SI-BONE to Participate in Upcoming Conferences

SANTA CLARA, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced t...

SI-BONE Q2 Sales Beat Estimates But Higher Costs Hit Profitability, Maintains FY21 Revenue Outlook

SI-BONE Inc (NASDAQ: SIBN) reported Q2 sales of $22.2 million, beating the consensus of $21.96 million, representing a 58% Y/Y increase over the COVID-19 impacted 2020 period. U.S. revenue of $20.2 mill...

SI-BONE: Q2 Earnings Insights

Shares of SI-BONE (NASDAQ:SIBN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 4.55% over the past year to ($0.42), which missed ...